TransMedics Group stock heads toward November 5 results

Published on 10/31/2026 at 00:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TransMedics Group stock will report third-quarter results after the market close on November 5. Management will host a call at 4:30 p.m. ET.

Results date sets the next focus

TransMedics will publish third-quarter 2026 results after the market close on November 5.
Management will discuss the results during a conference call at 4:30 p.m. Eastern Time.
The company develops portable technologies for organ preservation, assessment and transplantation.

TMDX, US89377M1099, Illustration mit AI erstellt.

TransMedics Group set November 5 as the release date for its third-quarter 2026 results in a company announcement on October 22. The report is due after the market close, with management scheduled to discuss the figures during a conference call at 4:30 p.m. Eastern Time. The announcement was published by TransMedics.

TransMedics Group stock traded at 58.88 euros on Lang & Schwarz at 23:00 CEST on Friday, October 30, 2026. The upcoming results are the next scheduled event for investors following the company's second-quarter reporting cycle.

Investors await the third quarter

The November release will give investors a fresh view of revenue development, profitability and management's outlook for the remainder of 2026. The accompanying call may provide additional detail on demand for the company's organ-care platform and the pace of commercial expansion.

TransMedics Group has scheduled further investor appearances after the results, including fireside chats at healthcare conferences in November and December. Those events could extend management's discussion of the business and its operating priorities.

For the real-time quote of TransMedics Group stock, investors can follow the latest Lang & Schwarz market indication.

TransMedics serves transplant medicine

TransMedics is a medical technology company headquartered in Andover, Massachusetts. It develops portable extracorporeal warm perfusion and assessment technologies for donor organs. Its platform is designed to preserve organ quality, assess organ viability before transplantation and potentially expand the use of donor organs for patients with end-stage heart, lung and liver failure.